Acrivon (ACRV) Chief Legal Officer has 558 shares withheld for RSU taxes

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine tax-related share disposition. On the vesting of restricted stock units, 558 shares of common stock were withheld by the company at $1.78 per share to satisfy mandatory tax withholding obligations.

After this withholding, Miller directly holds 33,121 shares of Acrivon common stock. The filing shows no open-market purchases or sales, only this non-discretionary tax-withholding event tied to equity compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miller Mary

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	558	$1.78	$993.24

Holdings After Transaction: Common Stock — 33,121 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 558 shares Withholding price per share: $1.78 per share Shares held after transaction: 33,121 shares

3 metrics

Shares withheld for taxes 558 shares Withheld to satisfy mandatory tax withholding on RSU vesting

Withholding price per share $1.78 per share Value used for 558 withheld shares

Shares held after transaction 33,121 shares Direct holdings of Mary Miller following tax withholding

Key Terms

restricted stock units, mandatory tax withholding requirement, Form 4, Chief Legal Officer

4 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirement financial

"to satisfy the mandatory tax withholding requirement"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Legal Officer financial

"officer_title": "Chief Legal Officer""

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		F(1)		558	D	$1.78	33,121	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Mary Miller?

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller had 558 common shares withheld to cover taxes on vested restricted stock units. This was a non-discretionary tax-withholding event, not an open-market stock sale or purchase, and was tied to her equity compensation.

Did Mary Miller of Acrivon (ACRV) sell shares in the open market?

No, Mary Miller did not sell shares in the open market. The 558 shares reported were withheld by Acrivon to satisfy mandatory tax withholding on vested restricted stock units, a common administrative step for equity awards rather than a voluntary stock sale.

How many Acrivon (ACRV) shares does Mary Miller hold after this Form 4?

After the tax-withholding transaction, Mary Miller directly holds 33,121 shares of Acrivon common stock. The Form 4 shows only 558 shares withheld for taxes on restricted stock unit vesting, with no additional reported purchases, sales, or derivative exercises in this filing.

What does the F transaction code mean in Acrivon (ACRV) Chief Legal Officer’s Form 4?

The F transaction code indicates shares were disposed of to pay an exercise price or tax liability. In this Acrivon filing, 558 shares were withheld by the issuer to meet mandatory tax withholding on vested restricted stock units, rather than being sold through the open market.

Is the Mary Miller Form 4 for Acrivon (ACRV) a routine equity compensation event?

Yes, the Form 4 reflects a routine equity compensation event. It shows 558 shares of common stock withheld by Acrivon to satisfy mandatory tax withholding on restricted stock unit vesting, leaving Mary Miller with 33,121 directly held shares afterward and no reported open-market trading.